

Resource Summary Report

Generated by [NIF](#) on Sep 9, 2026

HNT-34

RRID:CVCL_2071

Type: Cell Line

Proper Citation

RRID:CVCL_2071

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_2071

Proper Citation: RRID:CVCL_2071

Description: Cell line HNT-34 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Adult acute myeloid leukemia

Defining Citation: [PMID:9266939](#), [PMID:10071072](#), [PMID:10576511](#), [PMID:10637496](#), [PMID:10739008](#), [PMID:11226526](#), [PMID:16408098](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:30894373](#), [PMID:31068700](#)

Comments: Population: Japanese., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HNT-34

Synonyms: HNT34

Cross References: CLO:CLO_0050982, EFO:EFO_0006583, ArrayExpress:E-MTAB-2706, BioSample:SAMN01821631, BioSample:SAMN03472915, BioSample:SAMN10989583, cancercellines:CVCL_2071, Cell_Model_Passport:SIDM01621, Cosmic:787435, Cosmic:975253, Cosmic:1012069, Cosmic:1281316, Cosmic:2306209, Cosmic:2378086, DepMap:ACH-000299, DSMZ:ACC-600, DSMZCellDive:ACC-600, EGA:EGAS00001000610, EGA:EGAS00001002554, FANTOM5_SSTAR:10831-111D3, GEO:GSM1446757, PharmacDB:HNT34_558_2019, RCB:RCB1296, Wikidata:Q54890075

ID: CVCL_2071

Record Creation Time: 20220427T220438+0000

Record Last Update: 20260905T180455+0000

Ratings and Alerts

No rating or validation information has been found for HNT-34.

No alerts have been found for HNT-34.

Data and Source Information

Source: [CelloSaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Biernacki MA, et al. (2025) SF3B1K700E Neoantigen Is a CD8+ T-cell Target Shared across Human Myeloid Neoplasms. Cancer immunology research, 13(9), 1391.

Schmitt N, et al. (2025) The bispecific innate cell engager AFM28 eliminates CD123+ leukemic stem and progenitor cells in AML and MDS. Nature communications, 16(1), 7793.

Birdwell CE, et al. (2024) Preclinical efficacy of targeting epigenetic mechanisms in AML with 3q26 lesions and EVI1 overexpression. Leukemia, 38(3), 545.

DeVilbiss AW, et al. (2021) Metabolomic profiling of rare cell populations isolated by flow cytometry from tissues. eLife, 10.